Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal

Pfizer may be getting out of neurosciences work, but Shire $SHPG is stepping up its game. Shire is creating two separate drug divisions to help sharpen its focus on neurosciences. After a business review Shire says that it has determined that it will be better able to make strategic investments in the field if they carve out neurosciences. The news comes alongside a warning that Shire will fall well short of its announced goal of hitting $20 billion in revenue in 2020, which it promised in the wake of the Baxalta buyout. The new goal is $17 billion to $18 billion. Shire is also prepping a spinout of its ADHD group as it focuses more on rare diseases.

Agenus $AGEN is picking up $28 million after negotiating a $230 million royalty deal with HealthCare Royalty Partners. The biotech is redeeming its royalty bond from Oberland with the added monies to advance registrational studies with anti-CTLA-4 and anti-PD-1.

→ As the fight on hereditary ATTR (hATTR) amyloidosis between Ionis and Alnylam intensifies, Ionis $IONS announced today that inotersen has been granted priority review at the FDA, with the PDUFA date set on July 6, 2018. This comes just one day after Alnylam $ALNY took global rights to patisiran — which treats the same rare disease — back from Sanofi in a major deal restructuring.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->